 | Parts of this article (those related to Entire article) need to be updated. The reason given is: hasn't been materially touched since 2014. (August 2022) |
 | |
| Company type | Public |
|---|---|
| Nasdaq: RGEN S&P 400 Component | |
| Industry | Pharmaceutical industry |
| Founded | 1981 |
| Founders | Alexander Rich Paul Schimmel |
| Headquarters | Waltham, Massachusetts , United States |
Key people | Tony J. Hunt (president and CEO) |
| Products | Materials used in the manufacture of biological drugs |
| Revenue |  US$68 million (2014) |
| US$23 million (2014) | |
| Total assets | US$119 million (2014) |
| Total equity | US$104 million (2014) |
Number of employees | 116 (2014) |
| Website | repligen |
Repligen Corporation is an American company devoted to the development and production of materials used in the manufacture of biological drugs.2014 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981.[1] A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN.[2] In February 2014, Repligen had employed 116 people, about 50% of these based in Sweden.[3]
- ^ Repligen 2013 10-K 2014, p. 2.
- ^ Nasdaq: RGEN
- ^ Repligen 2013 10-K 2014, p. 6.